Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For inclusion in the study subjects should fulfill the following criteria:
- Provision of informed consent prior to any study specific procedures
- Males and females aged 19 years and older
- Congruent to the PLATO trial, at least two of the following three criteria have to be met:
- ST-segment changes on electrocardiography, indicating ischemia; (In electrocardiography, the ST segment connects the QRS complex and the T wave and has a duration of 0.080 to 0.120 sec (80 to 120 ms).
- a positive test of a biomarker, indicating myocardial necrosis; or one of several risk factors;
- age >60 years
- previous myocardial infarction or Coronary-Artery Bypass Grafting [CABG];
- coronary artery disease with stenosis of ≥50% in at least two vessels;
- previous ischemic stroke, transient ischemic attack, carotid stenosis of at least 50%, or cerebral revascularization;
- diabetes mellitus;
- peripheral arterial disease;
- or chronic renal dysfunction, defined as a creatinine clearance of <60 ml per minute per 1.73 m2 of body surface area).
- patients with symptoms of unstable angina lasting ≥10 min and either an elevated troponin I level or newly developed ST-segment depression of 1 mm or transient ST-segment elevation of 1 mm will also be included.
Exclusion Criteria:
Subjects should not enter the study if any of the following exclusion criteria are fulfilled:
- Patients with active pathological bleeding or a history of intracranial bleeding;
- patients with planned to urgent coronary artery bypass graft surgery;
- severe hepatic impairment;
- concomitant therapy with a strong cytochrome P-450 3A inhibitors, where 3A is s subfamily of the cytochrome P450 superfamily of genes;
- surgery<4 weeks;
- the use of any thienopyridine (within the previous two weeks);
- upstream use of Glycoprotein (GP) IIb/IIIa inhibitors;
- bleeding diathesis or major bleeding episode within 2 weeks;
- a need for oral anticoagulation therapy;
- thrombocytopenia;
- presence of thrombus in the coronary artery; incessant chest pain or hemodynamic instability;
- and patients with glomerular filtration rate (GFR)<30 mL/min or on hemodialysis.
- maintenance dose of aspirin above 100mg
- history of allergies to Ticagrelor
- patients at increased risk of bradycardic events (e.g., patients who have sick sinus syndrome, 2nd or 3rd degree Atrioventricular block (AV block), or bradycardic related syncope and not protected with a pacemaker
- women who are pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Ticagrelor and Eptifibatide bolus
Ticagrelor 180 mg i.v.
Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
|
Ticagrelor loading dose
Other Names:
i.v. infusion
Other Names:
|
|
Active Comparator: Ticagrelor & Eptifibatide bolus+infusion
Ticagrelor 180 mg i.v.
Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
|
Ticagrelor loading dose
Other Names:
i.v. infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Percent Inhibition of Platelet Aggregation (%IPA)
Time Frame: Baseline and 2 hours
|
Change from baseline in %IPA at 2 hours after stimulation with 20µM ADP (µM-micromolar, ADP-Adenosine diphosphate), measured in blood by an aggregometer among patients randomized to ticagrelor and 2 boluses of eptifibatide vs. ticagrelor and 2 boluses plus infusion of eptifibatide.
|
Baseline and 2 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
High On-treatment Platelet Reactivity (HPR)
Time Frame: Comparing baseline and follow-up (2 hours)
|
Percentage of participants with HPR.
HPR is defined as platelet aggregation >59% in response to 20 µM ADP.
|
Comparing baseline and follow-up (2 hours)
|
|
Bleeding Complications
Time Frame: up to 24 hours
|
Number of subjects that developed gastrointestinal bleeding after Percutaneous Coronary Intervention (PCI).
These subjects were categorized under Bleeding Academic Research Consortium 3b.
Type 3b bleeding includes overt bleeding plus a hemoglobin drop of ≥5 g/dL (provided the hemoglobin drop is related to bleeding), cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid), and bleeding requiring intravenous vasoactive drugs.
|
up to 24 hours
|
|
Periprocedural Myocardial Infarction (PMI)
Time Frame: Up to 24 hours
|
Number of subjects that developed PMI.
Periprocedural myocardial infarction (PMI) was defined as an increase in troponin I values >5 x 99th percentile the upper limit of normal in patients with normal baseline value on admission, or a rise of troponin I values >20% after PCI if the baseline value was elevated.
|
Up to 24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Massoud Leesar, MD, University of Alabama at Birmingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Acute Coronary Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Ticagrelor
- Eptifibatide
Other Study ID Numbers
Other Study ID Numbers
- ISSBRIL0077
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.